Abstract Details

Title Impact of Pubertal Status on the Prevalence of Primary Headache Disorder Among Female School Children in Kuwait.

Topic Headache

Presentation(s) P15 - Poster Session 15 (12:00 PM-1:00 PM)

Poster/Presentation
Number 7-012

Objective We sought to examine the impact of pubertal status on the prevalence of primary headache disorder among female school children in Kuwait.

Background Primary headaches are a common disorder among children and are increasingly reported in younger populations. Puberty has been postulated to share an association with the occurrence of primary headaches in children. Thus, they may account for differences in prevalence of headaches among prepubertal girls and adolescents. Thorough understanding of this association can have substantial implications on predicting trends and management of primary headaches in girls.

Design/Methods We conducted a cross-sectional study whereby female students (n = 669) completed a questionnaire concerning the frequency and nature of headaches. We randomly selected schools located in two governorates in Kuwait: AlFarwaneya (the largest) and Hawalli (urban location).

Results The mean age of the participants was 11.5 +/- 2.11 years. A diagnosis of primary headache was significantly associated with pubertal status among female students (p <.0001) with more pubertal females (64.26%) having a primary headache than prepubertal females (34.18%). Among prepubertal females, tension type headache was the most frequent type (17.35%), whereas pubertal females reported more migraine headaches (33.57%) than any other type.

Conclusions Puberty shares a significant association with primary headache disorder in female children with more frequent episodes reported among pubertal and adolescent females. This implies a potential role for puberty in the development of primary headache disorder. More research is warranted to further delineate the mechanistic ground for this association.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Samar F. Ahmed, MD	Dr. Ahmed has nothing to disclose.
Raed Alroughani, MD, F�鶹��ýӳ��	Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, AstraZeneca, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AstraZeneca, Biogen, Novartis, Merck, Roche, Sanofi.
Jasem Y. Al-Hashel, MD (IBN Sina Hospital, AlSabah Medical Area, Neurology Department)	Dr. Al-Hashel has nothing to disclose.

�鶹��ýӳ��

�鶹��ýӳ��